An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Trial Profile

An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms GALTON
  • Sponsors Genentech
  • Most Recent Events

    • 25 Jun 2017 Final results for the 36-months follow-up presented at the 22nd Congress of the European Haematology Association.
    • 04 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Aug 2013 Planned end date changed from 1 Apr 2016 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top